INS and kidney disorder: Despite this, patients receiving dulaglutide had a significantly lower eGFR decrease compared with insulin, again suggesting that HbA1c alone does not drive the kidney-protective effects observed with GLP-1 RAs.22 The reason why the benefits seen might be greater in people with established kidney disease is uncertain.